EP2916867A4 - Compositions and methods for modulating cell signaling - Google Patents

Compositions and methods for modulating cell signaling

Info

Publication number
EP2916867A4
EP2916867A4 EP13853885.5A EP13853885A EP2916867A4 EP 2916867 A4 EP2916867 A4 EP 2916867A4 EP 13853885 A EP13853885 A EP 13853885A EP 2916867 A4 EP2916867 A4 EP 2916867A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
cell signaling
modulating cell
modulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13853885.5A
Other languages
German (de)
French (fr)
Other versions
EP2916867A2 (en
Inventor
Timothy Alan Springer
Leonard Ira Zon
Nagesh K Mahanthappa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Scholar Rock Inc
Original Assignee
Childrens Medical Center Corp
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp, Scholar Rock Inc filed Critical Childrens Medical Center Corp
Publication of EP2916867A2 publication Critical patent/EP2916867A2/en
Publication of EP2916867A4 publication Critical patent/EP2916867A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP13853885.5A 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling Withdrawn EP2916867A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722969P 2012-11-06 2012-11-06
US201261722919P 2012-11-06 2012-11-06
PCT/US2013/068613 WO2014074532A2 (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Publications (2)

Publication Number Publication Date
EP2916867A2 EP2916867A2 (en) 2015-09-16
EP2916867A4 true EP2916867A4 (en) 2016-10-05

Family

ID=50685303

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13853885.5A Withdrawn EP2916867A4 (en) 2012-11-06 2013-11-06 Compositions and methods for modulating cell signaling

Country Status (10)

Country Link
US (2) US20150284455A1 (en)
EP (1) EP2916867A4 (en)
JP (3) JP2016500704A (en)
AU (3) AU2013341353B2 (en)
CA (2) CA2890733A1 (en)
IL (1) IL238488B (en)
MX (1) MX2015005675A (en)
SG (2) SG10201704616SA (en)
WO (1) WO2014074532A2 (en)
ZA (1) ZA201502884B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4342995A3 (en) 2006-03-31 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2009041643A1 (en) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
JP4954326B2 (en) 2008-04-11 2012-06-13 中外製薬株式会社 Antigen-binding molecules that repeatedly bind to multiple molecules of antigen
EP4231014A3 (en) 2010-11-30 2024-03-20 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
NZ705370A (en) 2012-08-24 2018-06-29 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
WO2014141064A1 (en) 2013-03-13 2014-09-18 Novartis Ag Notch2 binding molecules for treating respiratory diseases
KR102318483B1 (en) 2013-04-02 2021-10-27 추가이 세이야쿠 가부시키가이샤 Fc region variant
AU2014262843B2 (en) 2013-05-06 2017-06-22 Scholar Rock, Inc. Compositions and methods for growth factor modulation
JP7348708B2 (en) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Combination vaccine device and method for killing cancer cells
CA3005158A1 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016077526A1 (en) 2014-11-12 2016-05-19 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
MY181199A (en) * 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
CN107530423B (en) 2015-01-14 2022-04-05 布里格姆及妇女医院股份有限公司 Treatment of cancer with anti-LAP monoclonal antibodies
CN107108729A (en) 2015-02-05 2017-08-29 中外制药株式会社 The antibody of antigen-binding domains comprising ion concentration dependence, FC region variants, the binding antibodies of IL 8, and its application
AU2016297248A1 (en) * 2015-07-22 2018-02-15 Scholar Rock, Inc. GDF11 binding proteins and uses thereof
IL258121B2 (en) 2015-09-15 2024-01-01 Scholar Rock Inc Anti-pro/latent-myostatin antibodies and uses thereof
TWI836305B (en) * 2015-09-24 2024-03-21 日商第一三共股份有限公司 Anti-garp antibody and producing method and use thereof
CN116217729A (en) 2015-11-12 2023-06-06 思进公司 Glycan interaction compounds and methods of use
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
MX2018008369A (en) 2016-01-08 2019-05-15 Scholar Rock Inc Anti-pro/latent myostatin antibodies and methods of use thereof.
CN109072197A (en) 2016-02-06 2018-12-21 哈佛学院校长同事会 It is immune to rebuild to remold hematopoiesis nest
MX2018010948A (en) 2016-03-11 2019-06-20 Scholar Rock Inc TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF.
CN109310757A (en) * 2016-03-31 2019-02-05 爱西里斯药物技术有限公司 Nitroxoline and its analog and the combined use of chemotherapy and immunotherapy in cancer treatment
EP3785728A3 (en) 2016-06-13 2021-04-28 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
WO2018013797A1 (en) 2016-07-13 2018-01-18 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
KR20230079499A (en) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Composition for prophylaxis or treatment of il-8 related diseases
CN109996817A (en) * 2016-09-15 2019-07-09 艾科赛扬制药股份有限公司 Reverse primitive gut embryogenesis polypeptide and application thereof
DK3565592T3 (en) 2017-01-06 2023-05-01 Scholar Rock Inc TREATMENT OF METABOLIC DISEASES BY INHIBITION OF MYSTATIN ACTIVATION
AU2018255244A1 (en) 2017-04-21 2019-10-31 Mellitus, Llc Methods and antibodies for diabetes-related applications
EP4286013A3 (en) 2017-05-09 2024-02-28 Scholar Rock, Inc. Lrrc33 inhibitors and use thereof
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
ES2905160T3 (en) 2018-07-11 2022-04-07 Scholar Rock Inc Selective inhibitors of the TGFBeta1 isoform and their use
TW202035445A (en) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 Anti-lap antibody variants and uses thereof
MX2021009175A (en) 2019-01-30 2021-09-14 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFß AND USES THEREOF.
EP3966227A1 (en) 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
US20220308072A1 (en) 2019-08-12 2022-09-29 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
AU2020340176A1 (en) 2019-08-28 2022-04-14 Chugai Seiyaku Kabushiki Kaisha Cross-species anti-latent TGF-beta 1 antibodies and methods of use
CN111474336B (en) * 2020-03-21 2023-07-28 南昌大学 Preparation method of nickel ferricyanide nanoparticle luminescent aptamer sensor and method for detecting 8-OhdG based on nickel ferricyanide nanoparticle luminescent aptamer sensor
WO2022099093A1 (en) * 2020-11-06 2022-05-12 President And Fellows Of Harvard College Scaffolds for enhancing neutrophils and uses thereof
WO2022132666A1 (en) 2020-12-14 2022-06-23 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
CN113061575B (en) * 2021-03-25 2023-04-07 中国人民解放军陆军军医大学 Method for separating and purifying inherent lymphoid cells from colon inherent layer of old mouse
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
CN115286701A (en) * 2022-03-07 2022-11-04 江苏靶标生物医药研究所有限公司 Target for regulating intestinal mucosa homeostasis or inflammatory bowel disease of mammals and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009812A1 (en) * 1992-10-26 1994-05-11 Kirin Brewery Company, Limited METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
US5972335A (en) * 1994-03-29 1999-10-26 The Victoria University Of Manchester Wound healing
WO2007050793A2 (en) * 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
JP3452946B2 (en) * 1992-02-19 2003-10-06 協和醗酵工業株式会社 Anti-TGF-β masking protein monoclonal antibody
US5616561A (en) * 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US20080206219A1 (en) * 2003-08-08 2008-08-28 The Regencts Of The University Of California Novel Indications for Transforming Growth Factor-Beta Regulators
JPWO2006106599A1 (en) * 2005-03-01 2008-09-11 国立大学法人京都大学 Medicament for the prevention and / or treatment of diseases caused by abnormal enhancement of extracellular domain shedding
JP5634272B2 (en) * 2008-03-14 2014-12-03 ヒューマンザイム リミテッド Recombinant production of authentic human protein using human cell expression system
GB0809592D0 (en) * 2008-05-27 2008-07-02 Imp Innovations Ltd Biomaterials

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009812A1 (en) * 1992-10-26 1994-05-11 Kirin Brewery Company, Limited METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
US5972335A (en) * 1994-03-29 1999-10-26 The Victoria University Of Manchester Wound healing
WO2007050793A2 (en) * 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MINLONG SHI ET AL: "Latent TGF-[beta] structure and activation", NATURE, vol. 474, no. 7351, 15 June 2011 (2011-06-15), pages 343 - 349, XP055167968, ISSN: 0028-0836, DOI: 10.1038/nature10152 *

Also Published As

Publication number Publication date
AU2013341353A1 (en) 2015-05-28
SG11201503271XA (en) 2015-05-28
JP2016500704A (en) 2016-01-14
CA2890733A1 (en) 2014-05-15
IL238488B (en) 2020-04-30
WO2014074532A2 (en) 2014-05-15
US20150284455A1 (en) 2015-10-08
CA3023553A1 (en) 2014-05-15
WO2014074532A3 (en) 2014-06-26
AU2019264599A1 (en) 2019-12-05
SG10201704616SA (en) 2017-07-28
ZA201502884B (en) 2016-01-27
AU2013341353B2 (en) 2017-03-16
JP2019163317A (en) 2019-09-26
IL238488A0 (en) 2015-06-30
US20200024339A1 (en) 2020-01-23
AU2017203805A1 (en) 2017-06-22
AU2017203805B2 (en) 2019-08-15
JP2017132796A (en) 2017-08-03
EP2916867A2 (en) 2015-09-16
MX2015005675A (en) 2016-02-03

Similar Documents

Publication Publication Date Title
ZA201502884B (en) Compositions and methods for modulating cell signaling
HK1211623A1 (en) Cell lines
HK1212597A1 (en) Compositions for modulating c9orf72 expression c90rf72
ZA201409229B (en) Compositions and methods for modulating utrn expression
IL237156B (en) Microcapsule compositions and methods
EP2850184A4 (en) Compositions and methods for modulating gene expression
EP2850183A4 (en) Compositions and methods for modulating gene expression
EP2850189A4 (en) Compositions and methods for modulating gene expression
AP2014008100A0 (en) Compositions and methods for modulating hemoglobingene family expression
SG11201408697QA (en) Methods and compositions for natural killer cells
EP2906696A4 (en) Methods for modulating c9orf72 expression
EP2836212A4 (en) Novel compositions and methods
EP2850182A4 (en) Compositions and methods for modulating atp2a2 expression
ZA201300319B (en) Compositions and methods for modulating the wnt signaling pathway
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EP2850187A4 (en) Compositions and methods for modulating pten expression
EP2849800A4 (en) Compositions and methods for modulating bdnf expression
HK1205189A1 (en) Methods and compositions for modulating factor vii expression vii
EP2911230A4 (en) Cell
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
HK1220389A1 (en) Methods and compositions for modulating regulatory cell function
HK1210436A1 (en) Novel cell compositions and methods
EP2827861A4 (en) Composition and methods for cell modulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150413

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20160509BHEP

Ipc: A61K 39/395 20060101AFI20160509BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20160902

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20160829BHEP

Ipc: A61K 39/395 20060101AFI20160829BHEP

17Q First examination report despatched

Effective date: 20180213

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20200513